This screen identified activation of the RAS/MAPK/ERK pathway as one major mechanism of resistance to Syk inhibitors, which was further validated in AML cell lines with innate and acquired resistance to Syk inhibitors. This evidence concerns the gene SYK and acute myeloid leukemia.